Literature DB >> 16435194

Cumulative incidence rates of the mucopolysaccharidoses in Germany.

F Baehner1, C Schmiedeskamp, F Krummenauer, E Miebach, M Bajbouj, C Whybra, A Kohlschütter, C Kampmann, M Beck.   

Abstract

In order to estimate the cumulative incidence rates of the mucopolysaccharidoses (MPS) in Germany, a retrospective epidemiological survey covering the period between 1980 and 1995 was implemented. Multiple ascertainment sources were used to identify affected patients. A prevalence of approximately 0.69 cases per 100,000 births was obtained for MPS I (Hurler phenotype). Within the study period, 4 patients with Hurler/Scheie phenotype and 7 cases with Scheie disease were detected. The cumulative incidence for MPS II (Hunter syndrome) was estimated as 0.64 cases per 100,000 births (1.3 cases per 100,000 male live births); that for MPS III (Sanfilippo syndrome types A, B and C) as 1.57 cases in 100,000 births; that for MPS IV A (Morquio syndrome) as 0.38 cases in 100,000; and that for MPS VI (Maroteaux-Lamy syndrome) as 0.23 cases per 100,000 births. Two cases of MPS IVB (beta-galactosidase deficiency) have been identified, but no patients with MPS VII or MPS IX. A relatively high number of patients with MPS IIIB, MPS IVA and MPS VI were of Turkish origin. The crude rate for all types of mucopolysaccharidoses is approximately 3.53 cases in 100,000 live births. The cumulative incidence pattern of MPS in Germany was compared with the corresponding rates among other industrial nations obtained from recent literature: the crude cumulative rates for all types of mucopolysaccharidoses (3.4-4.5 in 100,000 live births) were similar among all published populations; however, different frequencies of the various forms of MPS were observed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16435194     DOI: 10.1007/s10545-005-0112-z

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  22 in total

1.  An update on the frequency of mucopolysaccharide syndromes in British Columbia.

Authors:  R B Lowry; D A Applegarth; J R Toone; E MacDonald; N Y Thunem
Journal:  Hum Genet       Date:  1990-08       Impact factor: 4.132

Review 2.  Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.

Authors:  G Yogalingam; J J Hopwood
Journal:  Hum Mutat       Date:  2001-10       Impact factor: 4.878

3.  Relative frequency of the Hurler and Hunter syndromes.

Authors:  R B Lowry; D H Renwick
Journal:  N Engl J Med       Date:  1971-01-28       Impact factor: 91.245

Review 4.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.

Authors:  N E Breslow; N E Day
Journal:  IARC Sci Publ       Date:  1987

5.  Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes.

Authors:  B Weber; X H Guo; W J Kleijer; J J van de Kamp; B J Poorthuis; J J Hopwood
Journal:  Eur J Hum Genet       Date:  1999-01       Impact factor: 4.246

6.  Mucopolysaccharidosis type I: identification of 13 novel mutations of the alpha-L-iduronidase gene.

Authors:  S Bunge; W J Kleijer; C Steglich; M Beck; E Schwinger; A Gal
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

7.  Low beta-glucuronidase enzyme activity and mutations in the human beta-glucuronidase gene in mild mucopolysaccharidosis type VII, pseudodeficiency and a heterozygote.

Authors:  R Vervoort; R Gitzelmann; N Bosshard; I Maire; I Liebaers; W Lissens
Journal:  Hum Genet       Date:  1998-01       Impact factor: 4.132

8.  The frequency of lysosomal storage diseases in The Netherlands.

Authors:  B J Poorthuis; R A Wevers; W J Kleijer; J E Groener; J G de Jong; S van Weely; K E Niezen-Koning; O P van Diggelen
Journal:  Hum Genet       Date:  1999 Jul-Aug       Impact factor: 4.132

Review 9.  Enzyme replacement and enhancement therapies for lysosomal diseases.

Authors:  R J Desnick
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 10.  Incidence of the mucopolysaccharidoses in Western Australia.

Authors:  John Nelson; June Crowhurst; Bill Carey; Lawrence Greed
Journal:  Am J Med Genet A       Date:  2003-12-15       Impact factor: 2.802

View more
  124 in total

1.  Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI.

Authors:  Sean Turbeville; Helen Nicely; J Douglas Rizzo; Tanya L Pedersen; Paul J Orchard; Mitchell E Horwitz; Edwin M Horwitz; Paul Veys; Carmem Bonfim; Amal Al-Seraihy
Journal:  Mol Genet Metab       Date:  2010-10-25       Impact factor: 4.797

2.  Sonographic ocular findings in patients with mucopolysaccharidoses I, II and VI.

Authors:  Reinhard G Schumacher; Rita Brzezinska; Gudrun Schulze-Frenking; Susanne Pitz
Journal:  Pediatr Radiol       Date:  2008-02-26

Review 3.  Gene therapy for mucopolysaccharidosis.

Authors:  Katherine P Ponder; Mark E Haskins
Journal:  Expert Opin Biol Ther       Date:  2007-09       Impact factor: 4.388

4.  Detection by Urinary GAG Testing of Mucopolysaccharidosis Type II in an At-Risk Spanish Population.

Authors:  Laura López-Marín; Luis G Gutiérrez-Solana; Luis Aldamiz-Echevarria Azuara; Rogelio Simón de Las Heras; Anna Duat Rodríguez; Verónica Cantarín Extremera
Journal:  JIMD Rep       Date:  2013-02-02

5.  Three Adult Siblings with Mucopolysaccharidosis Type II (Hunter Syndrome): A Report on Clinical Heterogeneity and 12 Months of Therapy with Idursulfase.

Authors:  Michel C Tchan; Kerry T Devine; David O Sillence
Journal:  JIMD Rep       Date:  2011-06-22

6.  Successful noninvasive ventilation and enzyme replacement therapy in an adult patient with morbus hunter.

Authors:  M Westhoff; P Litterst
Journal:  JIMD Rep       Date:  2011-12-16

7.  Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA.

Authors:  Robin K Rumsey; Kyle Rudser; Kathleen Delaney; Michael Potegal; Chester B Whitley; Elsa Shapiro
Journal:  J Pediatr       Date:  2014-02-25       Impact factor: 4.406

8.  Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (Hunter syndrome).

Authors:  Sung Yoon Cho; Rimm Huh; Mi Sun Chang; Jieun Lee; Younghee Kwun; Se Hyun Maeng; Su Jin Kim; Young Bae Sohn; Sung Won Park; Eun-Kyung Kwon; Sun Ju Han; Jooyoun Jung; Dong-Kyu Jin
Journal:  J Korean Med Sci       Date:  2014-01-28       Impact factor: 2.153

9.  Novel heparan sulfate assay by using automated high-throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses.

Authors:  Tsutomu Shimada; Joan Kelly; William A LaMarr; Naomi van Vlies; Eriko Yasuda; Robert W Mason; William Mackenzie; Francyne Kubaski; Roberto Giugliani; Yasutsugu Chinen; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji E Orii; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2014-07-21       Impact factor: 4.797

10.  Review of the use of idursulfase in the treatment of mucopolysaccharidosis II.

Authors:  T Andrew Burrow; Nancy D Leslie
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.